Guj. Themis Bio.

GUJTHEMIS29 Apr 2024

Pharmaceuticals

₹

-0.50 (-0.12%)

Lowest Today

Highest Today

Prev. Close

Today’s Open

52 Week High

52 Week Low

BUY

SELL

To Invest in Guj. Themis Bio.

Guj. Themis Bio.

Pharmaceuticals

GUJTHEMIS29 Apr 2024

₹

-0.50 (-0.12%)

OverviewFundamentals

Corporate action

Peer comparison

Income Sheet

Balance sheet

Cash flow

Share holding

About Us

Corporate Action

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

All

Dividends

Bonus

Splits

Others

Ex-Date	Type	Description	Record Date
13-May-2023	S	The Board of Directors at its meeting held today, considered and approved the following matters: The Board considered the proposal for sub-division of 1 equity share of the Company having face value of Rs.5/- each info 5 (five) equity shares having face value of Rs.1/- each, subject to regulatory/statutory approvals as may be required and the approval of the shareholders of the Company for the financial year 2023-24. 5. The Board considered the proposal for sub-division of 1 equity share of the Company having face value of Rs.5/- each into 5 (five) equity shares having face value of Rs.1/- each, subject to regulatory/statutory approvals as may be required and the approval of the shareholders of the Company for the financial year 2023-24. Further, the Board recommended consequential amendments in the Capital Clause of the Memorandum of Association of the Company and Articles of Association of the Company, subject to approval of the Shareholders of the Company. The record date for the sub-division of equity shares shall be decided by the Board and will be intimated to the exchanges. The detailed disclosure as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations. 2015 read with SEBI Circular No. CIR/CFD/CMD/ 4/2015 dated September 9, 2015 is enclosed herewith as Annexure ll. Please find our intimation under Regulation 42 of the SEBI (LODR) Regulations, 2015 (As Per BSE Announcement dated on 20.09.2023) Trading Members of the Exchange are hereby informed that GUJARAT THEMIS BIOSYN LTD., has fixed Record Date for the purpose of Sub-Division of the Equity Shares of the Company :- DEMATERIALISED SECURITIES - ROLLING SETTLEMENT SEGMENT COMPANY NAME & CODE GUJARAT THEMIS BIOSYN LTD. (506879) RECORD DATE 10/10/2023 PURPOSE Subdivision of existing Equity Shares from One Equity Share of Rs.5/- each into Five Equity Shares of Re. 1/- each. SUB-DIVIDED PAID-UP VALUE Re.1/- SUB-DIVIDED PAID-UP VALUE W.E.F. 10/10/2023 DR-630/2023-2024 Note: - i. ISIN No. INE942C01029 of Rs. 5/- paid up will not be valid for transactions done on the Exchange on or after 10/10/2023. ii. The new ISIN Number for Re. 1/- paid up will be informed to the market by a separate notice. (As Per BSE Announcement Dated on 25.09.2023) In Continuation of Notice No. 20230926-36 dated September 26, 2023, Trading Members of the Exchange are hereby informed that the New ISIN number for the Sub-Divided Equity Shares of the Company will be as under: - Company Name & Scrip Code GUJARAT THEMIS BIOSYN LTD. (506879) New ISIN No. INE942C01045 Remarks Sub-division of Equity Shares from Rs.5/- to Re.1/- The new ISIN number given above, for Equity Shares of Re.1/- each of the Company shall be effective for trades done on and from the Ex-Date i.e. 10-10-2023 (DR-630/2023-2024) (As Per BSE Notice Dated on 05.10.2023)	10-Oct-2023
10-Feb-2024	D	Please refer the attached intimation Declaration of an Interim Dividend for the Financial Year 2023-24 of ? 0.75/- (Rupee SeventyFive paise only) per equity share having face value of ? 1/- i.e. 75.00% aggregating to? 5,44,82,632.50/- (Rupees Five Crore Forty-Four Lakhs Eighty-Two Thousand Six Hundred andThirty-Two and Fifty Paise only	22-Feb-2024
13-May-2023	D	The Board of Directors at its meeting held today, considered and approved the following matters: Recommended dividend for Financial Year ended 31.03.2023 of Rs.1/- i.e. @ 20% per equity share having face value of Rs.5/- , aggregating to Rs. 1,45,28,702. The payment is subject to the approval of shareholders at the ensuing AGM	01-Sep-2023
21-Nov-2022	D	Meeting Commencement Time : 10:00 A.M Meeting Conclusion Time : 10:51 A.M The Board of Directors at its meeting held today, considered and approved the following: Declaration of an Interim Dividend for the Financial Year 2022-23 of 4.40/- (Rupees Four and forty paise only) per equity share having face value of 5/- i.e. 88% aggregating to 6,39,26,289/- (Rupees Six Crore Thirty Nine lakhs twenty six thousand two hundred eighty nine only)	01-Dec-2022
20-May-2022	D	Gujarat Themis Biosyn Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 20, 2022, inter alia, has recommended dividend for Financial Year ended March 31, 2022 of Rs. 4.00/- i.e. @ 80% per equity share having face value of Rs. 5/-, aggregating to Rs. 5.81 Crores. The payment is subject to the approval of shareholders at the ensuing AGM.	29-Aug-2022
11-Nov-2021	D	Declaration of an Interim dividend for Financial Year 2021-2022 of Rs.7/-(Rs. 2 plus an additional Rs.5 on the completion of forty years of establishment of the Company) (Rupee Seven only.) per equity share having face value of Rs.5/- i.e. 140% aggregating to Rs. 10.17 Crore. 3. The Record Date for the same is November 18 2021.	24-Nov-2021
15-Nov-2021	D	Declaration of an Interim dividend for Financial Year 2021-2022 of Rs.7/-(Rs. 2 plus an additional Rs.5 on the completion of forty years of establishment of the Company) (Rupee Seven only.) per equity share having face value of Rs.5/- i.e. 140% aggregating to Rs. 10.17 Crore. 3. The Record Date for the same is November 18 2021.	24-Nov-2021
18-May-2020	D	Gujarat Themis Biosyn Ltd has informed BSE that the Board of Directors at its meeting held on May 18, 2020, inter alia, has recommended dividend for Financial Year ended March 31, 2020 of Rs.1.65/- (Re One and paise sixty five only.) i.e. @ 33% per equity share having face value of Rs.5/- each, aggregating to Rs. 239.72 lacs. The payment is subject to the approval of shareholders at the ensuing AGM.	10-Sep-2020
10-Feb-2024	BC	Please refer the attached intimation Declaration of an Interim Dividend for the Financial Year 2023-24 of ? 0.75/- (Rupee SeventyFive paise only) per equity share having face value of ? 1/- i.e. 7	31-Mar-2024
10-Feb-2024	BC	Please refer the attached intimation	22-Feb-2024
12-Feb-2024	BC	75% Interim Dividend	22-Feb-2024
29-Jan-2024	BC	GUJARAT THEMIS BIOSYN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2024 inter alia to consider and approve Un-audited Financial Results for the	10-Feb-2024
29-Dec-2023	BC	Pharmaceutical Business Group India Ltd	27-Dec-2023

Announcement Date10-Feb-2024

Ex Dividend Date22-Feb-2024

Dividend(%)75

Announcement Date13-May-2023

Ex Dividend Date01-Sep-2023

Dividend(%)20

Announcement Date21-Nov-2022

Ex Dividend Date01-Dec-2022

Dividend(%)88

Announcement Date20-May-2022

Ex Dividend Date29-Aug-2022

Dividend(%)80

Announcement Date11-Nov-2021

Ex Dividend Date24-Nov-2021

Dividend(%)40

Announcement Date15-Nov-2021

Ex Dividend Date24-Nov-2021

Dividend(%)100

Announcement Date18-May-2020

Ex Dividend Date10-Sep-2020

Dividend(%)33

No Rights has been declared by GUJTHEMIS

Book Closure

Record Date	Split Date	Purpose
31-Mar-2024	-	Please refer the attached intimation Declaration of an Interim Dividend for the Financial Year 2023-24 of ? 0.75/- (Rupee SeventyFive paise only) per equity share having face value of ? 1/- i.e. 7
22-Feb-2024	-	Please refer the attached intimation
22-Feb-2024	-	75% Interim Dividend
10-Feb-2024	-	GUJARAT THEMIS BIOSYN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2024 inter alia to consider and approve Un-audited Financial Results for the
27-Dec-2023	-	Pharmaceutical Business Group India Ltd

Peer Comparison

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Scrip Name	Price	Daily Change	M.Cap (Cr)	1 Year Returns %	P/E (TTM)	PB Ratio
Gujarat Themis Biosyn Ltd ₹408.20(-0.50/-0.12%)	408.20	-0.50	2,968.94	169.86	53.99	16.68
Astrazeneca Pharma India Ltd ₹5,556.10(+140.70/2.60%)	5,556.10	+140.70	13,538.50	71.09	84.88	20.67
Bliss GVS Pharma Ltd ₹124.45(+1.85/1.51%)	124.45	+1.85	1,283.51	60.79	18.80	1.31
Cipla Ltd ₹1,407.55(-1.85/-0.13%)	1,407.55	-1.85	113,794.25	54.54	34.60	4.40
Abbott India Ltd ₹26,277.60(+412.75/1.60%)	26,277.60	+412.75	54,962.81	15.87	47.98	17.68
Amrutanjan Health Care Ltd ₹709.40(+28.55/4.19%)	709.40	+28.55	1,968.38	13.21	44.73	7.51

Income Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Gross Sales	38.86	39.65	49.59	28.17	28.17	47.69
Excise Duty	0.00	0.00	0.00	0.00	0.00	0.00
Net Sales	38.86	39.65	49.59	28.17	28.17	47.69
Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
Other Income	1.00	1.00	1.07	1.40	1.81	1.40
Total Income	39.86	40.65	50.66	29.57	29.97	49.09
Total Expenditure	21.11	22.83	26.08	13.25	16.05	23.29
PBIDT	18.75	17.82	24.58	16.33	13.92	25.80
Interest	0.08	0.05	0.03	0.02	0.07	0.04
PBDT	18.67	17.77	24.56	16.30	13.85	25.76
Depreciation	0.98	0.88	0.75	0.77	0.66	0.58
Tax	4.61	4.23	5.99	3.83	3.20	6.21
Deferred Tax	0.07	0.11	0.10	0.01	0.18	0.27
Reported Profit After Tax	13.01	12.54	17.72	11.69	9.81	18.70
Extra-ordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
Adjusted Profit After Extra-ordinary item	13.01	12.54	17.72	11.69	9.81	18.70

EPS (Unit Curr.)	1.79	8.63	12.20	8.05	6.75	12.87
EPS (Adj) (Unit Curr.)	1.79	1.73	2.44	1.61	1.35	2.57
Calculated EPS (Unit Curr.)	1.79	8.63	12.20	8.05	6.75	12.87
Calculated EPS (Adj) (Unit Curr.)	1.79	1.73	2.44	1.61	1.35	2.57
Calculated EPS (Ann.) (Unit Curr.)	7.17	34.53	48.79	32.19	27.00	51.48
Calculated EPS (Adj) (Ann.) (Unit Curr.)	7.17	6.91	9.76	6.44	5.40	10.30
Book Value (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend (%)	75.00	0.00	0.00	0.00	88.00	0.00
Equity	7.26	7.26	7.26	7.26	7.26	7.26
Reserve & Surplus	0.00	0.00	0.00	0.00	0.00	0.00
Face Value	1.00	5.00	5.00	5.00	5.00	5.00

Public Shareholding (No. Of Shares)	0.00	0.00	0.00	0.00	0.00	0.00
Public Shareholding (% in Equity)	0.00	0.00	0.00	0.00	0.00	0.00

Pledged/Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

Non Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

PBIDTM(%)	48.25	44.94	49.57	57.97	49.41	54.10
PBDTM(%)	48.04	44.82	49.53	57.86	49.17	54.02
PATM(%)	33.48	31.63	35.73	41.50	34.82	39.21

Balance Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18
SOURCES OF FUNDS :
Share Capital	7.26	7.26	7.26	7.26	7.26	7.26
Reserves Total	141.88	96.06	62.68	34.93	11.26	4.85
Equity Share Warrants	0.00	0.00	0.00	0.00	0.00	0.00
Equity Application Money	0.00	0.00	0.00	0.00	0.00	0.00
Total Shareholders Funds	149.14	103.32	69.94	42.19	18.52	12.11
Secured Loans	0.00	0.00	0.00	0.00	0.01	0.00
Unsecured Loans	0.42	1.17	4.83	8.15	6.00	0.59
Total Debt	0.42	1.17	4.83	8.15	6.01	0.59
Total Liabilities	149.56	104.49	74.77	50.34	24.53	12.70
APPLICATION OF FUNDS :
Gross Block	44.04	28.24	25.52	21.93	18.10	12.86
Less : Accumulated Depreciation	11.38	8.81	6.57	4.85	3.49	2.27
Less:Impairment of Assets	0.00	0.00	0.00	0.00	0.00	0.00
Net Block	32.66	19.43	18.95	17.08	14.61	10.59
Lease Adjustment	0.00	0.00	0.00	0.00	0.00	0.00
Capital Work in Progress	20.59	12.70	2.07	0.36	0.95	0.17
Producing Properties	0.00	0.00	0.00	0.00	0.00	0.00
Investments	0.00	0.00	0.00	0.01	0.01	0.01
Current Assets, Loans & Advances	0.00	0.00	0.00	0.00	0.00	0.00
Inventories	14.62	11.61	6.05	6.03	0.34	0.46
Sundry Debtors	17.91	25.12	14.71	20.23	5.80	2.72
Cash and Bank	9.33	12.35	27.64	2.08	1.70	4.46
Loans and Advances	18.99	29.31	14.92	0.79	0.20	0.19
Total Current Assets	60.85	78.39	63.33	29.13	8.03	7.84
Less : Current Liabilities and Provisions	0.00	0.00	0.00	0.00	0.00	0.00
Current Liabilities	14.06	14.47	10.58	11.64	6.72	7.27
Provisions	0.80	1.94	1.42	0.74	0.08	0.06
Total Current Liabilities	14.86	16.40	12.00	12.38	6.80	7.33
Net Current Assets	45.99	61.98	51.33	16.75	1.23	0.50
Miscellaneous Expenses not written off	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Assets	0.35	0.35	0.32	0.00	0.00	0.00
Deferred Tax Liability	1.65	1.38	1.30	0.86	0.92	0.00
Net Deferred Tax	-1.30	-1.03	-0.98	-0.86	-0.92	0.00
Total Assets	97.95	93.08	71.37	33.34	15.88	11.27
Contingent Liabilities	4.03	4.00	3.88	3.72	3.64	2.93

Cash Flow

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

PARTICULARS	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019
Cash and Cash Equivalents at Beginning of the year	0.26	3.97	0.86	1.12	0.89
Net Cash from Operating Activities	39.50	40.31	10.53	0.63	0.69
Net Cash Used In Investing Activities	-20.41	-29.83	-2.25	-2.98	-5.75
Net Cash Used In Financing Activities	-13.30	-14.00	-5.16	2.10	5.29
Net Inc./Dec In Cash And Cash Equivalents	5.79	-3.51	3.12	-0.26	0.23
Cash And Cash Equivalents At End Of The Year	6.06	0.46	3.97	0.86	1.12

Share Holding

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Promoter Shareholding

70.86%

FII Shareholding

1.05%

DII Shareholding

0.82%

Public Shareholding

27.26%

**Promoter pledged shareholding 70.86%

About Gujarat Themis Biosyn Ltd

Gujarat Themis Biosyn Ltd is in the Pharmaceuticals sector, having a market capitalization of Rs. 2968.94 crores. It has reported a sales of Rs. 38.86 crores and a net profit of Rs. 13.01 crores for the quarter ended December 2018. The company management includes Dinesh S Patel, Dinesh S Patel,Sachin D Patel,VIJAY GOPI KISHAN AGARWAL,Kirandeep Madan,Vikram D Sanghvi,Siddharth Y Kusumgar (Gujarat Themis Biosyn Ltd) among others.

Chairman

Dinesh S Patel

Registered office

69/C GIDC Industrial Estate,Valsad Dist,VAPI,Gujarat,396195

FAX :91-260-2400639

Background

Incorporation Year1981

Face Value₹1

Market Lot1

How to buy Guj. Themis Bio. shares on nse?

To buy Guj. Themis Bio. shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified

What is the Guj. Themis Bio. share price today?

The Guj. Themis Bio. shares price on nse is Rs.408.2 today.

What is the market cap of Guj. Themis Bio. shares on BSE ?

The company has a market capitalization of Rs.2968.94Cr

What is the PE & PB ratio of Guj. Themis Bio. shares ?

PE is 53.99 and PB is 16.68

What is the 52 Week High and Low of Guj. Themis Bio. shares?

Guj. Themis Bio. stock price high: Rs.423 Guj. Themis Bio. stock price low: Rs.145.41